| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 35 | 2024 | 1092 | 5.030 |
Why?
|
| MicroRNAs | 8 | 2022 | 518 | 2.360 |
Why?
|
| Transcription Factors | 8 | 2021 | 735 | 1.940 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2022 | 968 | 1.690 |
Why?
|
| Prostate | 7 | 2024 | 155 | 1.160 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 218 | 0.880 |
Why?
|
| Breast Neoplasms | 8 | 2022 | 1723 | 0.870 |
Why?
|
| Cell Line, Tumor | 27 | 2023 | 2676 | 0.820 |
Why?
|
| Prostatic Hyperplasia | 1 | 2024 | 32 | 0.820 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2023 | 15 | 0.790 |
Why?
|
| Cell Nucleus | 3 | 2014 | 383 | 0.790 |
Why?
|
| Humans | 66 | 2024 | 43102 | 0.790 |
Why?
|
| Male | 44 | 2024 | 23409 | 0.770 |
Why?
|
| Cell Movement | 5 | 2016 | 655 | 0.750 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2023 | 97 | 0.750 |
Why?
|
| Neoplasm Metastasis | 8 | 2021 | 237 | 0.640 |
Why?
|
| Cadherins | 6 | 2016 | 102 | 0.640 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 228 | 0.600 |
Why?
|
| Neuroendocrine Tumors | 3 | 2024 | 11 | 0.600 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2010 | 39 | 0.550 |
Why?
|
| Proteomics | 4 | 2022 | 378 | 0.530 |
Why?
|
| Receptors, Androgen | 1 | 2018 | 144 | 0.520 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 17 | 0.510 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 67 | 0.460 |
Why?
|
| Antigens, CD | 2 | 2016 | 127 | 0.460 |
Why?
|
| Epithelial Cells | 4 | 2017 | 434 | 0.460 |
Why?
|
| Cell Adhesion | 4 | 2016 | 238 | 0.450 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 99 | 0.450 |
Why?
|
| Cell Proliferation | 10 | 2021 | 1455 | 0.440 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 82 | 0.430 |
Why?
|
| Neoplasms | 6 | 2023 | 1377 | 0.420 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2014 | 31 | 0.420 |
Why?
|
| Neoplasm Invasiveness | 6 | 2016 | 290 | 0.410 |
Why?
|
| Mice | 15 | 2024 | 6644 | 0.400 |
Why?
|
| Cell Lineage | 1 | 2013 | 104 | 0.380 |
Why?
|
| Apoptosis | 9 | 2017 | 1568 | 0.360 |
Why?
|
| Dioxoles | 5 | 2012 | 8 | 0.350 |
Why?
|
| DNA Methylation | 3 | 2022 | 403 | 0.350 |
Why?
|
| Telomerase | 1 | 2011 | 42 | 0.350 |
Why?
|
| Receptors, Cell Surface | 3 | 2021 | 146 | 0.340 |
Why?
|
| Antineoplastic Agents | 5 | 2014 | 1019 | 0.340 |
Why?
|
| Peptides | 3 | 2023 | 372 | 0.340 |
Why?
|
| Isoquinolines | 5 | 2012 | 55 | 0.330 |
Why?
|
| Glycoproteins | 1 | 2011 | 125 | 0.330 |
Why?
|
| Animals | 20 | 2024 | 16992 | 0.330 |
Why?
|
| Duffy Blood-Group System | 2 | 2021 | 5 | 0.330 |
Why?
|
| Lymphatic Metastasis | 4 | 2024 | 81 | 0.320 |
Why?
|
| Hepatocytes | 2 | 2007 | 80 | 0.310 |
Why?
|
| Epigenesis, Genetic | 3 | 2024 | 291 | 0.290 |
Why?
|
| Kidney Transplantation | 2 | 2020 | 101 | 0.290 |
Why?
|
| Neoplasm Transplantation | 4 | 2021 | 129 | 0.290 |
Why?
|
| Noscapine | 3 | 2014 | 17 | 0.290 |
Why?
|
| Peptide Fragments | 1 | 2010 | 307 | 0.280 |
Why?
|
| Female | 19 | 2024 | 24698 | 0.280 |
Why?
|
| Mutation | 2 | 2022 | 1177 | 0.270 |
Why?
|
| RNA, Messenger | 3 | 2024 | 1271 | 0.260 |
Why?
|
| Signal Transduction | 10 | 2022 | 2157 | 0.260 |
Why?
|
| Bioreactors | 1 | 2007 | 30 | 0.250 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 101 | 0.250 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 224 | 0.240 |
Why?
|
| Flow Cytometry | 3 | 2016 | 411 | 0.240 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2021 | 95 | 0.230 |
Why?
|
| Epidermal Growth Factor | 2 | 2018 | 70 | 0.230 |
Why?
|
| Receptors, Calcitriol | 2 | 2023 | 69 | 0.230 |
Why?
|
| Mice, Nude | 5 | 2021 | 408 | 0.230 |
Why?
|
| Healthcare Disparities | 3 | 2022 | 590 | 0.230 |
Why?
|
| Hormone Antagonists | 1 | 2005 | 13 | 0.230 |
Why?
|
| Middle Aged | 9 | 2024 | 12222 | 0.220 |
Why?
|
| Protein Transport | 3 | 2014 | 296 | 0.210 |
Why?
|
| Axonemal Dyneins | 1 | 2024 | 6 | 0.210 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2024 | 8 | 0.210 |
Why?
|
| Coculture Techniques | 3 | 2010 | 109 | 0.210 |
Why?
|
| Cyclodextrins | 2 | 2014 | 11 | 0.200 |
Why?
|
| Trans Fatty Acids | 1 | 2023 | 5 | 0.200 |
Why?
|
| Aged | 6 | 2024 | 8214 | 0.200 |
Why?
|
| Adenocarcinoma | 3 | 2010 | 291 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 223 | 0.200 |
Why?
|
| Gallium Radioisotopes | 1 | 2023 | 3 | 0.200 |
Why?
|
| Drug Delivery Systems | 3 | 2017 | 277 | 0.200 |
Why?
|
| Bleomycin | 1 | 2023 | 20 | 0.200 |
Why?
|
| Living Donors | 2 | 2020 | 18 | 0.200 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2023 | 40 | 0.200 |
Why?
|
| Intestinal Neoplasms | 1 | 2022 | 6 | 0.190 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2024 | 131 | 0.190 |
Why?
|
| Alabama | 2 | 2020 | 52 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 31 | 0.180 |
Why?
|
| Quality of Life | 2 | 2024 | 616 | 0.180 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 91 | 0.170 |
Why?
|
| Endonucleases | 1 | 2021 | 18 | 0.170 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2021 | 5 | 0.170 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 5 | 0.170 |
Why?
|
| DNA Repair | 1 | 2022 | 198 | 0.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 384 | 0.170 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 495 | 0.170 |
Why?
|
| Vitamin D | 1 | 2022 | 196 | 0.170 |
Why?
|
| United States | 6 | 2024 | 5205 | 0.160 |
Why?
|
| Databases, Genetic | 2 | 2021 | 103 | 0.160 |
Why?
|
| Mannose-Binding Lectins | 1 | 2020 | 14 | 0.160 |
Why?
|
| Minority Groups | 3 | 2022 | 690 | 0.160 |
Why?
|
| Donor Selection | 1 | 2020 | 9 | 0.160 |
Why?
|
| Stomach Neoplasms | 1 | 2022 | 241 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2021 | 144 | 0.160 |
Why?
|
| Patient Advocacy | 1 | 2020 | 22 | 0.160 |
Why?
|
| Green Fluorescent Proteins | 2 | 2013 | 209 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 186 | 0.150 |
Why?
|
| Glycolysis | 2 | 2016 | 71 | 0.150 |
Why?
|
| Cytokines | 1 | 2023 | 678 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 27 | 0.150 |
Why?
|
| Stromal Cells | 2 | 2011 | 55 | 0.150 |
Why?
|
| Behavioral Research | 1 | 2019 | 41 | 0.140 |
Why?
|
| Nanoparticles | 2 | 2017 | 460 | 0.140 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 374 | 0.140 |
Why?
|
| Chemokines | 1 | 2019 | 96 | 0.140 |
Why?
|
| Minority Health | 1 | 2019 | 95 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2024 | 2544 | 0.140 |
Why?
|
| Quinazolines | 1 | 2018 | 38 | 0.140 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2017 | 16 | 0.140 |
Why?
|
| Health Services Accessibility | 2 | 2022 | 706 | 0.140 |
Why?
|
| Adult | 5 | 2024 | 13872 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 863 | 0.130 |
Why?
|
| Gene Silencing | 1 | 2018 | 154 | 0.130 |
Why?
|
| Ferric Compounds | 1 | 2017 | 62 | 0.130 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 40 | 0.130 |
Why?
|
| Serine Endopeptidases | 1 | 2017 | 48 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 154 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2016 | 84 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1285 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 3 | 2021 | 256 | 0.120 |
Why?
|
| Proteome | 1 | 2017 | 152 | 0.120 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 74 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 760 | 0.120 |
Why?
|
| Autoantibodies | 1 | 2016 | 117 | 0.120 |
Why?
|
| Galactans | 1 | 2014 | 2 | 0.110 |
Why?
|
| Cell Communication | 2 | 2007 | 114 | 0.110 |
Why?
|
| Mannans | 1 | 2014 | 5 | 0.110 |
Why?
|
| Plant Gums | 1 | 2014 | 7 | 0.110 |
Why?
|
| Incidence | 3 | 2024 | 1078 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 508 | 0.110 |
Why?
|
| Microspheres | 1 | 2014 | 49 | 0.110 |
Why?
|
| Mice, SCID | 2 | 2011 | 158 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 652 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2014 | 105 | 0.100 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 78 | 0.100 |
Why?
|
| Phenotype | 2 | 2014 | 780 | 0.100 |
Why?
|
| Keratin-14 | 1 | 2013 | 1 | 0.100 |
Why?
|
| Keratin-5 | 1 | 2013 | 6 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2019 | 502 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 526 | 0.100 |
Why?
|
| Integrases | 1 | 2013 | 28 | 0.100 |
Why?
|
| Ghana | 2 | 2023 | 36 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 592 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2021 | 196 | 0.100 |
Why?
|
| Sex Factors | 1 | 2016 | 1028 | 0.090 |
Why?
|
| Subcellular Fractions | 1 | 2012 | 77 | 0.090 |
Why?
|
| Caspase 3 | 2 | 2010 | 227 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 587 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 62 | 0.090 |
Why?
|
| Cell Aggregation | 1 | 2011 | 17 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2007 | 1766 | 0.090 |
Why?
|
| Ipomoea batatas | 1 | 2011 | 8 | 0.090 |
Why?
|
| Cell Cycle | 1 | 2013 | 346 | 0.090 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 95 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 88 | 0.090 |
Why?
|
| NF-kappa B | 1 | 2014 | 358 | 0.090 |
Why?
|
| Cell Separation | 1 | 2011 | 94 | 0.090 |
Why?
|
| ADAM Proteins | 1 | 2011 | 20 | 0.090 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 665 | 0.080 |
Why?
|
| Antitussive Agents | 1 | 2010 | 7 | 0.080 |
Why?
|
| Plant Leaves | 1 | 2011 | 136 | 0.080 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2010 | 10 | 0.080 |
Why?
|
| Epithelium | 1 | 2011 | 78 | 0.080 |
Why?
|
| Gene Expression | 1 | 2014 | 701 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 1124 | 0.080 |
Why?
|
| Cell Survival | 4 | 2017 | 945 | 0.080 |
Why?
|
| Immunity, Innate | 2 | 2022 | 171 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 704 | 0.080 |
Why?
|
| Tubulin Modulators | 1 | 2010 | 20 | 0.080 |
Why?
|
| Disease Progression | 1 | 2012 | 667 | 0.080 |
Why?
|
| Rats | 2 | 2007 | 3735 | 0.070 |
Why?
|
| Teniposide | 1 | 2008 | 1 | 0.070 |
Why?
|
| Mesoderm | 1 | 2008 | 73 | 0.070 |
Why?
|
| Endothelial Cells | 2 | 2012 | 329 | 0.070 |
Why?
|
| Lymphoma | 1 | 2008 | 41 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 133 | 0.070 |
Why?
|
| Tubulin | 1 | 2008 | 96 | 0.070 |
Why?
|
| Liver Circulation | 1 | 2007 | 1 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2011 | 561 | 0.060 |
Why?
|
| Perfusion | 1 | 2007 | 38 | 0.060 |
Why?
|
| Rats, Transgenic | 1 | 2007 | 34 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2021 | 223 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 436 | 0.060 |
Why?
|
| Equipment Design | 1 | 2007 | 145 | 0.060 |
Why?
|
| Mitochondria | 1 | 2010 | 523 | 0.060 |
Why?
|
| Carcinoma | 1 | 2007 | 108 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 2853 | 0.060 |
Why?
|
| Immunoblotting | 1 | 2005 | 181 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 83 | 0.050 |
Why?
|
| Muscle, Smooth | 1 | 2024 | 58 | 0.050 |
Why?
|
| Fatty Acid Desaturases | 1 | 2023 | 4 | 0.050 |
Why?
|
| Calorimetry, Differential Scanning | 2 | 2014 | 35 | 0.050 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 2 | 2014 | 83 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2024 | 93 | 0.050 |
Why?
|
| Systems Biology | 1 | 2022 | 27 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2024 | 183 | 0.050 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2023 | 65 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2023 | 240 | 0.050 |
Why?
|
| Estrogens | 1 | 2024 | 203 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 93 | 0.050 |
Why?
|
| Risk Factors | 2 | 2021 | 3994 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2023 | 134 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 81 | 0.050 |
Why?
|
| Thromboxane B2 | 1 | 2022 | 9 | 0.050 |
Why?
|
| Thromboxane A2 | 1 | 2022 | 20 | 0.050 |
Why?
|
| Endoplasmic Reticulum | 1 | 2022 | 108 | 0.040 |
Why?
|
| Chromatin | 1 | 2023 | 186 | 0.040 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2021 | 4 | 0.040 |
Why?
|
| Carcinoma, Large Cell | 1 | 2021 | 3 | 0.040 |
Why?
|
| Automation, Laboratory | 1 | 2021 | 2 | 0.040 |
Why?
|
| Internationality | 1 | 2021 | 37 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2021 | 17 | 0.040 |
Why?
|
| Aspirin | 1 | 2022 | 89 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2021 | 80 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2021 | 141 | 0.040 |
Why?
|
| Young Adult | 1 | 2012 | 5080 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2021 | 58 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 266 | 0.040 |
Why?
|
| Genomics | 1 | 2022 | 293 | 0.040 |
Why?
|
| G2 Phase | 2 | 2010 | 28 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2020 | 37 | 0.040 |
Why?
|
| Alleles | 1 | 2021 | 352 | 0.040 |
Why?
|
| Nigeria | 1 | 2019 | 92 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 259 | 0.040 |
Why?
|
| Mitosis | 2 | 2010 | 114 | 0.040 |
Why?
|
| Macrophages | 1 | 2023 | 529 | 0.040 |
Why?
|
| Registries | 1 | 2021 | 437 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 89 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2009 | 79 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 800 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 359 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 861 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 368 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2019 | 452 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 492 | 0.030 |
Why?
|
| Focus Groups | 1 | 2019 | 423 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 116 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 863 | 0.030 |
Why?
|
| Research Personnel | 1 | 2019 | 206 | 0.030 |
Why?
|
| Cultural Diversity | 1 | 2019 | 193 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2017 | 64 | 0.030 |
Why?
|
| Surface Properties | 1 | 2017 | 160 | 0.030 |
Why?
|
| Cell Line | 2 | 2010 | 1410 | 0.030 |
Why?
|
| Endocytosis | 1 | 2017 | 118 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2016 | 33 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 2016 | 20 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 1600 | 0.030 |
Why?
|
| Cell Death | 1 | 2017 | 278 | 0.030 |
Why?
|
| Particle Size | 1 | 2017 | 272 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 1759 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2017 | 388 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 1857 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2016 | 90 | 0.030 |
Why?
|
| Iron | 1 | 2017 | 251 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 280 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 408 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2014 | 60 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 64 | 0.030 |
Why?
|
| beta-Cyclodextrins | 1 | 2014 | 35 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2015 | 60 | 0.030 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2015 | 90 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 206 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2014 | 116 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 561 | 0.020 |
Why?
|
| Paxillin | 1 | 2012 | 5 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 28 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2019 | 719 | 0.020 |
Why?
|
| X-Ray Diffraction | 1 | 2012 | 66 | 0.020 |
Why?
|
| Centrosome | 1 | 2012 | 30 | 0.020 |
Why?
|
| Cell Polarity | 1 | 2012 | 57 | 0.020 |
Why?
|
| Solubility | 1 | 2012 | 139 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 173 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 536 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 138 | 0.020 |
Why?
|
| Microtubules | 1 | 2012 | 121 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2011 | 12 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 986 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 5 | 0.020 |
Why?
|
| Superoxides | 1 | 2011 | 57 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3156 | 0.020 |
Why?
|
| Integrins | 1 | 2011 | 54 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 301 | 0.020 |
Why?
|
| Androgens | 1 | 2010 | 106 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 152 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 34 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2009 | 76 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2009 | 98 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2009 | 157 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 462 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 347 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 161 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 694 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 1621 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 307 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 456 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 165 | 0.020 |
Why?
|
| Protein Binding | 1 | 2008 | 1082 | 0.010 |
Why?
|